All In Biotech

NDA 021976 · Janssen Prods

Prezista

Darunavir · Oral

NovelAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Mar 31, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jun 23, 2006

Approved uses

14

Original approval plus efficacy supplements

Registered trials

247

74 Phase 3, 6 recruiting

FAERS reports

15,121

13,236 serious, 1,506 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 29, 2025.

PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 )

Mechanism: Darunavir is an HIV-1 antiviral drug [see Microbiology (12.4) ] . Mechanism of Action Darunavir is an inhibitor of the HIV-1 protease. It selectively inhibits the cleavage of HIV-1 encoded Gag-Pol polyproteins in infected cells, thereby preventing the formation of mature virus particles.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • PREZISTA · DARUNAVIR 150MG · TABLET, ORAL · Prescription · TE AB
  • PREZISTA · DARUNAVIR 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • PREZISTA · DARUNAVIR 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • PREZISTA · DARUNAVIR 800MG · TABLET, ORAL · Prescription · TE AB
  • PREZISTA · DARUNAVIR 75MG · TABLET, ORAL · Prescription · TE AB
  • PREZISTA · DARUNAVIR 600MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Darunavir" as an intervention, any sponsor and status, largest first.

All 247 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • foetal exposure during pregnancy1,163
  • drug interaction992
  • pain891
  • emotional distress813
  • anxiety812
  • anhedonia705
  • chronic kidney disease572
  • exposure during pregnancy571
  • maternal exposure during pregnancy538
  • death500
  • diarrhoea500
  • renal failure498

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200621
2007211
2008395
2009524
2010535
2011427
2012646
2013816
2014878
20151,271
20161,295
2017982
20181,200
20191,174
20201,304
2021926
2022853
2023595
2024522
2025324
2026222

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prezista (Darunavir)

2024 spending

$24.7M

Beneficiaries

2,970

12,315 claims

Per beneficiary

$8,329

$53.75 per unit

View as table
YearSpending
2020$229,126,832
2021$202,037,571
2022$187,152,790
2023$133,001,203
2024$24,737,763

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 360 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.